Press Releases

INDIANAPOLIS, Dec. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced interim clinical data from the LOXO-305 global Phase 1/2 BRUIN dose escalation trial. LOXO-305 is an investigational, highly selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor. These data were presented today at the 2019 American Society of Hematology (ASH) Annual M

SOUTH SAN FRANCISCO, Calif., Dec. 8, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in patients with specific subtypes of T-cell Non-Hodgkin Lymphoma, including relapsed/refractory peripheral T-

SAN DIEGO, Dec. 8, 2019 /PRNewswire/ -- Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, announced today that its lead investigator, Dr

STOCKHOLM, Dec. 8, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present updated data from the ongoing Phase 2 ANCHOR (OP-104) triple combination study at the ASH Annual Meeting 2019. In the data presented, melflufen and dexamethasone demonstrated positive efficacy in combination with daratumumab or bortezomib in patients with re

TARRYTOWN, N.Y., Dec. 8, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced initial clinical data for REGN5458, a BCMAxCD3 bispecific antibody, in patients wit

CAMBRIDGE, Mass., Dec. 8, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced initial data from the Phase 2 PIONEER clinical trial of avapritinib in patients with indolent systemic mastocytosis (SM). Initial data from the dose-f

STOCKHOLM, Dec. 8, 2019 /PRNewswire/ -- Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™), presented results from an online survey highlighting disease burden and impact for patients with immune thrombocytopenia (ITP), at the 61st Annual Meeting of the American Society of Hematology (ASH) taking place in

BROOKLYN, N.Y., Dec. 8, 2019 /PRNewswire/ -- A computer betting game can help predict the likelihood that someone recovering from opioid addiction will reuse the pain-relieving drugs, a new study shows.

NEW BRUNSWICK, N.J., Dec. 8, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Janssen Pharmaceutical Companies will provide up to 200,000 Ebola vaccine regimens to the Republic of Rwanda. This commitment will support a new immunization program led by the Rwanda Government that aims to help protect the c

NORTH CHICAGO, Ill., Dec. 8, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today presented long-term data from a post-hoc analysis, further supporting the sustained clinical benefit of fixed duration treatment with VENCLEXTA®/VENCLYXTO® (venetoclax) in combination with rituximab (VenR) in patients with relapsed